Cellectis Overview
- Year Founded
-
1999
- Status
-
Public
- Employees
-
229
- Stock Symbol
-
ALCLS
- Investments
-
4
- Share Price
-
$1.00
- (As of Friday Closing)
Cellectis General Information
Description
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
Contact Information
Website
www.cellectis.comCorporate Office
- 8 rue de la Crolx Jarry
- 75013 Paris
- France
Corporate Office
- 8 rue de la Crolx Jarry
- 75013 Paris
- France
Cellectis Timeline
Cellectis Stock Performance
As of 20-Nov-2026, Cellectis’s stock price is $1.00. Its current market cap is $101M with 101M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.00 | $1.08 | $0.99 - $5.47 | $101M | 101M | 461K | -$1.26 |
Cellectis Financials Summary
As of 30-Sep-2026, Cellectis has a trailing 12-month revenue of $25.2M.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 70,771 | 396,781 | 11,975 | 236,295 |
| Revenue | 25,168 | 72,949 | 41,506 | 755 |
| EBITDA | (80,817) | (49,345) | (20,740) | (96,251) |
| Net Income | (127,376) | (67,593) | (36,761) | (101,059) |
| Total Assets | 213,425 | 324,720 | 383,544 | 334,270 |
| Total Debt | 89,076 | 90,733 | 91,461 | 85,056 |
Cellectis Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cellectis Comparisons
Industry
Financing
Details
Cellectis Competitors (85)
One of Cellectis’s 85 competitors is Coherus Oncology, a Formerly VC-backed company based in Redwood City, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Coherus Oncology | Formerly VC-backed | Redwood City, CA | ||||
| Polaris Group (Drug Discovery) | Formerly PE-Backed | Chengdu, China | ||||
| Northwest Biotherapeutics | Corporation | Bethesda, MD | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Valerio Therapeutics | Formerly VC-backed | Paris, France |
Cellectis Patents
Cellectis Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026195675-A1 | Mitochondrial base editors | Pending | 18-Mar-2025 | ||
| WO-2026046724-A1 | Tale protein scaffolds involving fusions of monopartite and bipartite nls | Pending | 30-Aug-2024 | ||
| WO-2025181336-A1 | Compositions and methods for hbb-editing in hspc | Pending | 01-Mar-2024 | ||
| WO-2025168476-A1 | Homogenization device | Pending | 05-Feb-2024 | ||
| WO-2024246301-A1 | Methods for identifying tale base editors off-sites | Inactive | 02-Jun-2023 | C12N15/102 |
Cellectis Signals
Cellectis Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Cellectis Investments & Acquisitions (4)
Cellectis’s most recent deal was a Corporate with Primera Therapeutics for . The deal was made on 29-Dec-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Primera Therapeutics | 29-Dec-2022 | Corporate | Biotechnology | ||
| Cellartis | 04-Nov-2011 | Merger/Acquisition | Biotechnology | ||
| Cyto Pulse Sciences | 02-Sep-2010 | Merger/Acquisition | Discovery Tools (Healthcare) | ||
| Vectocell Technology | 12-Oct-2009 | Corporate Asset Purchase | Buildings and Property |
Cellectis ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
41.2 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Cellectis Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Calyxt | Roseville, MN | 2010 |
Cellectis FAQs
-
When was Cellectis founded?
Cellectis was founded in 1999.
-
Where is Cellectis headquartered?
Cellectis is headquartered in Paris, France.
-
What is the size of Cellectis?
Cellectis has 229 total employees.
-
What industry is Cellectis in?
Cellectis’s primary industry is Drug Discovery.
-
Is Cellectis a private or public company?
Cellectis is a Public company.
-
What is Cellectis’s stock symbol?
The ticker symbol for Cellectis is ALCLS.
-
What is the current stock price of Cellectis?
As of 20-Nov-2026 the stock price of Cellectis is $1.00.
-
What is the current market cap of Cellectis?
The current market capitalization of Cellectis is $101M.
-
What is Cellectis’s current revenue?
The trailing twelve month revenue for Cellectis is $25.2M.
-
Who are Cellectis’s competitors?
Coherus Oncology, Polaris Group (Drug Discovery), Northwest Biotherapeutics, Adaptimmune Therapeutics, and Valerio Therapeutics are some of the 85 competitors of Cellectis.
-
What is Cellectis’s annual earnings per share (EPS)?
Cellectis’s EPS for 12 months was -$1.26.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process